deciphera was established in 2003 based on a deep scientific understanding of kinase inhibitors and a team dedicated to developing sophisticated approaches to therapeutic targeting of kinases. with business and development operations based in boston, and dedicated research capabilities in close proximity to the university of kansas, deciphera has identified small molecule leads for over 50 kinase targets, and has developed a pipeline of small molecule drug candidates for a range of cancers.
Company profile
Ticker
DCPH
Exchange
Website
CEO
Steven Hoerter
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Deciphera Pharmaceuticals, LLC
SEC CIK
Corporate docs
Subsidiaries
Deciphera Pharmaceuticals, LLC • Deciphera Pharmaceuticals Securities Corporation ...
DCPH stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
21 Jun 24
EFFECT
Notice of effectiveness
14 Jun 24
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jun 24
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jun 24
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jun 24
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jun 24
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jun 24
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jun 24
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jun 24
S-8 POS
Registration of securities for employees (post-effective amendment)
11 Jun 24
Transcripts
DCPH
Earnings call transcript
2023 Q4
6 Feb 24
DCPH
Earnings call transcript
2023 Q3
30 Oct 23
DCPH
Earnings call transcript
2023 Q2
9 Aug 23
DCPH
Earnings call transcript
2023 Q1
3 May 23
DCPH
Earnings call transcript
2022 Q4
7 Feb 23
DCPH
Earnings call transcript
2022 Q3
3 Nov 22
DCPH
Earnings call transcript
2022 Q2
7 Aug 22
DCPH
Earnings call transcript
2022 Q1
8 May 22
DCPH
Earnings call transcript
2021 Q4
9 Feb 22
DCPH
Earnings call transcript
2021 Q3
3 Nov 21
Latest ownership filings
4
Matthew L Sherman
11 Jun 24
4
Thomas Patrick Kelly
11 Jun 24
4
Jama Pitman
11 Jun 24
4
Franklin Stuart Friedman
11 Jun 24
4
Susan L. Kelley
11 Jun 24
4
Dashyant Dhanak
11 Jun 24
4
John Richard Martin
11 Jun 24
4
Daniel C. Martin
11 Jun 24
4
Dennis Leo Walsh
11 Jun 24
4
James Arthur Bristol
11 Jun 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 91.23 mm | 91.23 mm | 91.23 mm | 91.23 mm | 91.23 mm | 91.23 mm |
Cash burn (monthly) | (no burn) | 1.95 mm | 16.28 mm | 17.21 mm | 18.20 mm | 12.65 mm |
Cash used (since last report) | n/a | 7.54 mm | 62.95 mm | 66.55 mm | 70.35 mm | 48.92 mm |
Cash remaining | n/a | 83.69 mm | 28.28 mm | 24.68 mm | 20.88 mm | 42.31 mm |
Runway (months of cash) | n/a | 42.9 | 1.7 | 1.4 | 1.1 | 3.3 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 173 |
Opened positions | 69 |
Closed positions | 11 |
Increased positions | 42 |
Reduced positions | 34 |
13F shares | Current |
---|---|
Total value | 905.43 bn |
Total shares | 89.20 mm |
Total puts | 27.60 k |
Total calls | 5.30 k |
Total put/call ratio | 5.2 |
Largest owners | Shares | Value |
---|---|---|
Brightstar Associates | 23.11 mm | $0.00 |
BLK Blackrock | 5.99 mm | $94.29 bn |
Armistice Capital | 5.90 mm | $92.81 bn |
Flynn James E | 5.79 mm | $0.00 |
Redmile | 5.30 mm | $83.32 bn |
Deerfield Management | 5.13 mm | $80.65 bn |
Vanguard | 4.57 mm | $71.81 bn |
STT State Street | 3.10 mm | $48.74 bn |
GS Goldman Sachs | 1.96 mm | $30.88 bn |
SVLSF Vi | 1.72 mm | $33.86 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Jun 24 | Benz Edward J. JR | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 14.91 | 30,000 | 447.30 k | 0 |
11 Jun 24 | Benz Edward J. JR | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 13.98 | 18,500 | 258.63 k | 0 |
11 Jun 24 | Benz Edward J. JR | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 21.05 | 12,000 | 252.60 k | 0 |
11 Jun 24 | Benz Edward J. JR | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 6.13 | 7,181 | 44.02 k | 0 |
11 Jun 24 | Benz Edward J. JR | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 3.95 | 35,233 | 139.17 k | 0 |
11 Jun 24 | Hoerter Steven L. | Common Stock | Dispose U | No | No | 0 | 72,763 | 0.00 | 0 | |
11 Jun 24 | Hoerter Steven L. | Common Stock | Sale back to company | Dispose D | No | No | 0 | 286,075 | 0.00 | 72,763 |
11 Jun 24 | Hoerter Steven L. | Common Stock | Grant | Acquire A | No | No | 0 | 286,075 | 0.00 | 358,838 |
11 Jun 24 | Hoerter Steven L. | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 15.92 | 298,100 | 4.75 mm | 0 |
11 Jun 24 | Hoerter Steven L. | Stock Option Common Stock | Sale back to company | Dispose D | No | No | 15.48 | 250,000 | 3.87 mm | 0 |
News
Guggenheim Downgrades Deciphera Pharmaceuticals to Neutral
30 Apr 24
Deep Dive Into Deciphera Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
30 Apr 24
Barclays Upgrades Deciphera Pharmaceuticals to Equal-Weight, Raises Price Target to $26
30 Apr 24
S&P 500 Edges Higher; ON Semiconductor Earnings Top Views
29 Apr 24
US Stocks Kick Off The Week In The Green, Tesla Rockets On China's FSD Approval, Yen Rallies: What's Driving Markets Monday?
29 Apr 24
Press releases
Ono Announces Results of Tender Offer to Acquire Deciphera Pharmaceuticals and Completion of Acquisition of Deciphera (a Wholly Owned Subsidiary of Ono)
11 Jun 24
Kuehn Law Encourages HIBB, CRGY, DCPH, and HCP Investors to Contact Law Firm
3 Jun 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, AGS, DCPH
30 May 24
SHAREHOLDER ALERT: Halper Sadeh LLC Continues to Investigate SQSP, DPSI, DCPH, HRT
29 May 24
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SQSP, AGS, DCPH
20 May 24